Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | BMC Cancer

Figure 4

From: Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes

Figure 4

Prostate cancer genes. A: Cancer expression of DLX1. Immunohistochemistry shows positive nuclei (three examples indicated by red arrows, left panel) of cancer cells (case 04-030E) strongly stained. Cancer glands are negative for basal CD104 (top right) and luminal CD10 (bottom right); original magnification 200×. B: Candidate prostate cancer biomarkers. Genes with increased expression (based on array signal values as used in Fig. 1C) in CD26+ cancer vs. luminal (arrowheads) that encode secreted - AGR2, CEACAM5, CRISP3, NEO1, membrane anchored - LOX, BCMP11 or transmembrane - KCNH8, KCNG3 proteins are shown. C: Western blot verification of AGR2 expression. In nearly all cases of CP except 08-032 (indicated by arrow), AGR2 protein was detected at higher levels. AGR2 in any matched NP samples may be derived from diffusion from the cancer foci. D: Candidate biomarkers from LNCaP. Through dataset analysis, these genes were found differentially expressed between CD10-/CD26+ cancer and CD10+/CD26- LNCaP.

Back to article page